Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edaravone + dexborneol for radiation-induced brain injury
ChiCTR2600125711Phase 2Not yet recruiting
- Sponsor
- Dongguan People's Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of edaravone dexborneol in radiation-induced encephalopathy (RIE), sponsored by Dongguan People's Hospital. Primary endpoint: Proportion of patients with ≥25% reduction in brain edema volume on FLAIR-MRI at 3 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
edaravone dexborneol
03
Conditions
radiation-induced encephalopathy (RIE)
Beyond the preview
Go deeper on ChiCTR2600125711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125711.